Tharimmune, Inc. | WebDisclosure

PRESS RELEASE

published on 05/19/2025 at 14:01, 1 year 1 month ago

Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Tharimmune, Inc. appoints James Gordon Liddy as strategic advisor for TH104 development, targeting high-potency opioid exposure. FDA feedback positive for prophylaxis indication

Tharimmune Inc. FDA Feedback High-Potency Opioids James Gordon Liddy TH104 Development
BRIEF

published on 05/06/2025 at 14:06, 1 year 1 month ago

Tharimmune Reports Positive Phase 1 Results for TH104

Tharimmune Inc. FDA Feedback Phase 1 Study Opioid Prophylaxis TH104 Buccal Film
BRIEF

published on 05/06/2025 at 14:06, 1 year 1 month ago

Tharimmune annonce des résultats positifs de phase 1 pour le TH104

Tharimmune Inc. Étude De Phase 1 Commentaires De La FDA Prophylaxie Aux Opioïdes Film Buccal TH104
PRESS RELEASE

published on 05/06/2025 at 14:01, 1 year 1 month ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Tharimmune, Inc. presents promising pharmacokinetic and metabolism data of TH104, a buccal film of nalmefene, for prophylaxis against opioid exposure. Study results showcased at Digestive Disease Week 2025

Tharimmune Inc. TH104 Buccal Film Pharmacokinetic Study Opioid Prophylaxis
BRIEF

published on 05/01/2025 at 14:06, 1 year 1 month ago

Le TH104 de Tharimmune sera présenté lors de conférences médicales importantes

Biopharmaceutique TH104 Tharimmune DDW 2025 EASL 2025
BRIEF

published on 05/01/2025 at 14:06, 1 year 1 month ago

Tharimmune's TH104 to Be Presented at Notable Medical Conferences

TH104 Biopharmaceutical Tharimmune DDW 2025 EASL 2025
PRESS RELEASE

published on 05/01/2025 at 14:01, 1 year 1 month ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
Tharimmune, Inc. announces presentation of clinical data on lead drug TH104 at DDW and EASL Annual Meetings in May 2025, addressing unmet medical needs in immunology & inflammation

Tharimmune Inc. TH104 Clinical Data Immunology Unmet Medical Needs
BRIEF

published on 04/30/2025 at 14:06, 1 year 1 month ago

Tharimmune élargit son conseil d'administration avec de nouvelles nominations

Stratégie De Croissance Biopharmaceutique Direction Nominations Au Conseil D'administration Tharimmune
BRIEF

published on 04/30/2025 at 14:06, 1 year 1 month ago

Tharimmune Expands Board with New Appointments

Growth Strategy Biopharmaceutical Leadership Board Appointments Tharimmune
PRESS RELEASE

published on 04/30/2025 at 14:01, 1 year 1 month ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
Tharimmune, Inc. appoints Clay Kahler and Gary Stetz to its Board of Directors, expanding to 9 members. Kahler brings life sciences expertise while Stetz contributes financial acumen

Board Of Directors Financial Expertise Tharimmune Clay Kahler Gary Stetz

Published on 06/27/2026 at 16:50, 4 hours 28 minutes ago

Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 19 hours 38 minutes ago

Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 21 hours 18 minutes ago

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 22 hours 18 minutes ago

Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 22 hours 28 minutes ago

Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada

View all ACCESSWIRE

Published on 06/27/2026 at 00:05, 21 hours 13 minutes ago

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 21 hours 14 minutes ago

Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 21 hours 42 minutes ago

Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 21 hours 42 minutes ago

EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 21 hours 51 minutes ago

EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE

View all EQS

Published on 06/26/2026 at 17:45, 1 day 3 hours ago

Combined General Meeting, June 25, 2026
Published on 06/26/2026 at 17:45, 1 day 3 hours ago

Assemblée générale mixte du 25 juin 2026
Published on 06/26/2026 at 17:45, 1 day 3 hours ago

Descriptif du programme de rachat d'actions
Published on 06/26/2026 at 14:44, 1 day 6 hours ago

Safran information
Published on 06/26/2026 at 14:44, 1 day 6 hours ago

Information Safran

View all LES ECHOS COMFI WIRE

News